


**Product Name** : Debio 0932  
**Cat. No.** : PC-49868  
**CAS No.** : 1061318-81-7  
**Molecular Formula** : C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>S  
**Molecular Weight** : 442.58  
**Target** : Heat Shock Protein (HSP)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Debio 0932 (CUDC-305, RGRN-305) is a highly potent, oral and BBB-penetrant **HSP90** inhibitor, shows high affinity for HSP90alpha/beta and HSP90 complex derived from cancer cells with IC<sub>50</sub> of 100 nM and 48.8 nM, respectively.

Debio 0932 (CUDC-305) displays potent antiproliferative activity against a broad range of cancer cell lines with mean IC<sub>50</sub> of 220 nM.

Debio 0932 (CUDC-305) exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.

Debio 0932 (CUDC-305) also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.

Debio 0932 (CUDC-305) binds strongly to HSP90 extracted from erlotinib-resistant NSCLC cells (IC<sub>50</sub>=70 nM).

Debio 0932 (CUDC-305) potently inhibits tumor growth in subcutaneous xenograft models of H1975 and A549, which harbor EGFR T790M mutation or K-ras mutations conferring acquired and primary erlotinib resistance, respectively.

## References

Bao R, et al. *Clin Cancer Res*. 2009 Jun 15;15(12):4046-57.

Bao R, et al. *Mol Cancer Ther*. 2009 Dec;8(12):3296-306.

Isambert N, et al. *Ann Oncol*. 2015 May;26(5):1005-1011.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com